Terms: = Breast cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Clinical Outcome
23 results:
1. Withaferin A mediated changes of miRNA expression in breast cancer-derived mammospheres.
Prajapati KS; Shuaib M; Gupta S; Kumar S
Mol Carcinog; 2022 Sep; 61(9):876-889. PubMed ID: 35770722
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract] [Full Text] [Related]
3. PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
Alfarsi LH; El Ansari R; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
BMC Cancer; 2020 May; 20(1):425. PubMed ID: 32410585
[TBL] [Abstract] [Full Text] [Related]
4. HiFreSP: A novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures.
Li M; Zhao J; Li X; Chen Y; Feng C; Qian F; Liu Y; Zhang J; He J; Ai B; Ning Z; Liu W; Bai X; Han X; Wu Z; Xu X; Tang Z; Pan Q; Xu L; Li C; Wang Q; Li E
Brief Bioinform; 2020 Jul; 21(4):1411-1424. PubMed ID: 31350847
[TBL] [Abstract] [Full Text] [Related]
5. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic breast cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract] [Full Text] [Related]
6. Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
Singla H; Kaur RP; Shafi G; Vashistha R; Banipal RPS; Kumar V; Munshi A
Mol Biol Rep; 2019 Feb; 46(1):823-831. PubMed ID: 30535550
[TBL] [Abstract] [Full Text] [Related]
7. Patterns of copy number alterations in primary breast tumors of South African patients and their impact on functional cellular pathways.
Lupicki K; Elifio-Esposito S; Fonseca AS; Weber SH; Sugita B; Langa BC; Pereira SRF; Govender D; Panieri E; Hiss DC; Abdul-Rasool S; Cavalli LR
Int J Oncol; 2018 Dec; 53(6):2745-2757. PubMed ID: 30320392
[TBL] [Abstract] [Full Text] [Related]
8. Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in cancer Cells.
Gendelman R; Xing H; Mirzoeva OK; Sarde P; Curtis C; Feiler HS; McDonagh P; Gray JW; Khalil I; Korn WM
Cancer Res; 2017 Apr; 77(7):1575-1585. PubMed ID: 28087598
[TBL] [Abstract] [Full Text] [Related]
9. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.
Absenger G; Szkandera J; Stotz M; Pichler M; Winder T; Langsenlehner T; Langsenlehner U; Samonigg H; Renner W; Gerger A
Mol Carcinog; 2013 Nov; 52 Suppl 1():E96-102. PubMed ID: 23625573
[TBL] [Abstract] [Full Text] [Related]
10. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Lundgren K; Brown M; Pineda S; Cuzick J; Salter J; Zabaglo L; Howell A; Dowsett M; Landberg G;
Breast Cancer Res; 2012 Apr; 14(2):R57. PubMed ID: 22475046
[TBL] [Abstract] [Full Text] [Related]
11. The Cyclin D1 (ccnd1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Labonte MJ; Wilson PM; Yang D; Zhang W; Ladner RD; Ning Y; Gerger A; Bohanes PO; Benhaim L; El-Khoueiry R; El-Khoueiry A; Lenz HJ
Ann Oncol; 2012 Jun; 23(6):1455-64. PubMed ID: 21989330
[TBL] [Abstract] [Full Text] [Related]
12. Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.
Lundgren K; Tobin NP; Lehn S; Stål O; Rydén L; Jirström K; Landberg G
J Mol Diagn; 2011 May; 13(3):340-51. PubMed ID: 21497294
[TBL] [Abstract] [Full Text] [Related]
13. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
Bertucci F; Borie N; Roche H; Bachelot T; Le Doussal JM; Macgrogan G; Debono S; Martinec A; Treilleux I; Finetti P; Esterni B; Extra JM; Geneve J; Hermitte F; Chabannon C; Jacquemier J; Martin AL; Longy M; Maraninchi D; Fert V; Birnbaum D; Viens P
Breast Cancer Res Treat; 2011 Jun; 127(2):363-73. PubMed ID: 20585850
[TBL] [Abstract] [Full Text] [Related]
14. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.
Bax DA; Mackay A; Little SE; Carvalho D; Viana-Pereira M; Tamber N; Grigoriadis AE; Ashworth A; Reis RM; Ellison DW; Al-Sarraj S; Hargrave D; Jones C
Clin Cancer Res; 2010 Jul; 16(13):3368-77. PubMed ID: 20570930
[TBL] [Abstract] [Full Text] [Related]
15. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.
Gruel N; Lucchesi C; Raynal V; Rodrigues MJ; Pierron G; Goudefroye R; Cottu P; Reyal F; Sastre-Garau X; Fourquet A; Delattre O; Vincent-Salomon A
Eur J Cancer; 2010 Sep; 46(13):2399-407. PubMed ID: 20570624
[TBL] [Abstract] [Full Text] [Related]
16. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.
Abramson VG; Troxel AB; Feldman M; Mies C; Wang Y; Sherman L; McNally S; Diehl A; Demichele A
Anticancer Res; 2010 Apr; 30(4):1279-85. PubMed ID: 20530440
[TBL] [Abstract] [Full Text] [Related]
17. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.
Millar EK; Dean JL; McNeil CM; O'Toole SA; Henshall SM; Tran T; Lin J; Quong A; Comstock CE; Witkiewicz A; Musgrove EA; Rui H; Lemarchand L; Setiawan VW; Haiman CA; Knudsen KE; Sutherland RL; Knudsen ES
Oncogene; 2009 Apr; 28(15):1812-20. PubMed ID: 19287456
[TBL] [Abstract] [Full Text] [Related]
18. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
Tan DS; Marchió C; Jones RL; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2008 Sep; 111(1):27-44. PubMed ID: 17922188
[TBL] [Abstract] [Full Text] [Related]
19. ccnd1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
[TBL] [Abstract] [Full Text] [Related]
20. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.
Brandt B; Meyer-Staeckling S; Schmidt H; Agelopoulos K; Buerger H
Clin Cancer Res; 2006 Dec; 12(24):7252-60. PubMed ID: 17189396
[TBL] [Abstract] [Full Text] [Related]
[Next]
